No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AMRX Amneal Pharmaceuticals
- 6.670
- -0.080-1.19%
Close Jul 5 16:00 ET
- 6.790
- +0.120+1.80%
Post 18:33 ET
2.06BMarket Cap-9136P/E (TTM)
6.740High6.595Low1.24MVolume6.740Open6.750Pre Close8.25MTurnover0.93%Turnover RatioLossP/E (Static)308.65MShares7.25052wk High-32.38P/B884.92MFloat Cap2.95052wk Low--Dividend TTM132.67MShs Float24.480Historical High--Div YieldTTM2.15%Amplitude1.240Historical Low6.675Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Amneal Pharmaceuticals (NASDAQ:AMRX) Doubles Its Share Value and Trade at a Discount
Teva Focus of FTC Investigation Over Inhaler Patents
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments
Amneal Pharmaceuticals (AMRX) said Monday that it has expanded its biosimilar portfolio to eight by adding ADL018, a proposed biosimilar of Novartis' (NVS) Xolair, or omalizumab, to its pipeline. The
Express News | Kashiv Biosciences, LLC - Financial Terms of Transaction Not Disclosed
Express News | Kashiv Biosciences Enters Into Exclusive Licensing Agreement With Amneal for Commercialization of a Proposed Biosimilar to Xolair® (Omalizumab)
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $8
Barclays analyst Balaji Prasad maintains $Amneal Pharmaceuticals(AMRX.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 45.4% a
Comments
$Amneal Pharmaceuticals(AMRX.US$ Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
$Amneal Pharmaceuticals(AMRX.US$ Amneal Launches PEMRYDI RTU, The First Ready-To-Use Version Of Important Oncology Injectable Medicine
Benzinga· 2 mins ago
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration
Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forward – this is the first of 2024
Benzinga· 2 mins ago
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration
Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forward – this is the first of 2024
$Amneal Pharmaceuticals(AMRX.US$ Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
1
$Amneal Pharmaceuticals(AMRX.US$
Wait for institutions to offer guidance before taking out gains !
Wait for institutions to offer guidance before taking out gains !
$Amneal Pharmaceuticals(AMRX.US$
DONT PaNICK
short sellers need to exit their position to cover, HOLD the GAIN(S)
DONT PaNICK
short sellers need to exit their position to cover, HOLD the GAIN(S)
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg